Company · NBIX
Neurocrine Biosciences
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
4
4 still marketed
Novel approvals
2
Approvals since 2021
5
Originals and new uses
Phase 3 trials
23
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Crenessity approved Breakthrough therapyPriority reviewOrphanDec 13, 2024
- Crenessity approved NovelBreakthrough therapyPriority reviewOrphanDec 13, 2024
- Ingrezza Sprinkle approved OrphanApr 30, 2024
- Ingrezza new use OrphanAug 18, 2023
- Ingrezza new use Apr 23, 2021
- Ingrezza approved NovelBreakthrough therapyPriority reviewOrphanApr 11, 2017
Drugs in development (7)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- NBI-1065845TAK-653, OsavampatorPhase 35 trials
Neurocrine Biosciences · Major Depressive Disorder
- NBI-1117568Phase 35 trials
Neurocrine Biosciences · Schizophrenia, Bipolar I Disorder, Mania
- NBI-1065890Phase 21 trial
Neurocrine Biosciences · Tardive Dyskinesia
- NBI-1070770Phase 21 trial
Neurocrine Biosciences · Major Depressive Disorder
- NBI-1117567Phase 21 trial
Neurocrine Biosciences · Alzheimer's Disease
- NBI-1117570Phase 21 trial
Neurocrine Biosciences · Schizophrenia
- NBIP-01435Phase 21 trial
Neurocrine Biosciences · Congenital Adrenal Hyperplasia
Recruiting Phase 3 trials
Largest first.
- Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06966401 · 850 participants (planned) · Start Apr 16, 2025 · Primary completion May 2029
Drug: NBI-1065845 · For: Major Depressive Disorder
Sites: Huntsville, Alabama; Bryant, Arkansas; Little Rock, Arkansas · 120 sites in all
- NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaPivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07114874 · 600 participants (planned) · Start Jul 11, 2025 · Primary completion Dec 2031
Drug: NBI-1117568 · For: Schizophrenia
Sites: Bryant, Arkansas; Little Rock, Arkansas; Cerritos, California · 61 sites in all
- Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaPivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07227818 · 560 participants (planned) · Start Dec 16, 2025 · Primary completion Jul 2029
Drug: NBI-1117568; Placebo · For: Schizophrenia
Sites: Garden Grove, California; La Habra, California; Lemon Grove, California · 25 sites in all
- A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07196501 · 550 participants (planned) · Start Aug 18, 2025 · Primary completion Jul 2028
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Oceanside, California; Orange, California; San Jose, California · 61 sites in all
- NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaPivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06963034 · 284 participants (planned) · Start May 8, 2025 · Primary completion Oct 2027
Drug: NBI-1117568; Placebo · For: Schizophrenia
Sites: Bryant, Arkansas; Little Rock, Arkansas; Anaheim, California · 21 sites in all
- NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaPivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07105098 · 284 participants (planned) · Start Aug 11, 2025 · Primary completion Nov 2027
Drug: NBI-1117568; Placebo · For: Schizophrenia
Sites: Little Rock, Arkansas; Culver City, California; Garden Grove, California · 20 sites in all
- NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06963021 · 200 participants (planned) · Start May 30, 2025 · Primary completion Jul 2027
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Chino, California; Los Angeles, California; Stanford, California · 39 sites in all
- Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06786624 · 200 participants (planned) · Start Jan 22, 2025 · Primary completion Jul 2027
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Garden Grove, California; Orange, California · 30 sites in all
- NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06911112 · 200 participants (planned) · Start Mar 31, 2025 · Primary completion Jul 2027
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Huntsville, Alabama; Bryant, Arkansas; Cerritos, California · 42 sites in all
Marketed drugs (4)
Newest FDA action first.
- Ingrezza Valbenazine Tosylate · 2017
- Ingrezza Sprinkle Valbenazine Tosylate · 2024
- Crenessity Crinecerfont · 2024
- Crenessity Crinecerfont · 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.